In the News
OncLive
April 7, 2023
For many patients, there is no greater sense of promise than cancer immunotherapy and it is often the first inquiry we receive. Of course, the concept of cancer immunotherapy is not new, dating back 150 years when William B.
Targeted Oncology
March 27, 2023
Results from the phase 1/2 study were presented by Bockorny, the principal investigator, during The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer. Results suggested that the clinical benefit of botensilimab plus bastiliimab was superior to that of standard-of-care therapy.
OncLive
March 27, 2023
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.
Fierce Biotech
March 27, 2023
A year and a half after Agenus withdrew its accelerated approval request for cervical cancer drug balstilimab, the biotech has provided new combo data in ovarian cancer.
ASCO Post
March 10, 2023
In heavily pretreated patients with metastatic colorectal cancer who have microsatellite-stable tumors, the novel combination of the monoclonal antibodies botensilimab and balstilimab showed clinical activity, producing durable responses and an estimated 63% overall survival rate at 12 months, according to a phase Ia/IIb study reported at the 2023 ASCO GI Cancers Symposium.
Dana Farber Cancer Institute
March 1, 2023
Colorectal cancer is the 3rd most common cancer among men and women of all ages in the US and is on track to be the leading cause of cancer death in adults under 50 by 2030. The alarming rise of colorectal cancer in people younger than 50 prompted the US Preventive Services Task Force to lower the colorectal cancer screening age from 50 to 45 in 2021.
Targeted Oncology
February 15, 2023
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, senior physician at Dana-Farber Cancer Institute and instructor in Medicine at Harvard Medical School, discuses new studies in the gastrointestinal cancers space. Schlechter explains how these studies can inform future research.
ASCO Post
January 23, 2023
A combination of the next-generation immunotherapies botensilimab and balstilimab showed clinical activity in treating patients with refractory metastatic microsatellite-stable (MSS) colorectal cancer, according to new findings presented by El-Khoueiry et al at the 2023 ASCO Gastrointestinal Cancers Symposium (Abstract LBA8).
Fierce Biotech
January 23, 2023
Fifteen months after the FDA blindsided Agenus with a decision not to offer accelerated approval for the cervical cancer drug balstilimab, the biotech is back with fresh data for a combo featuring the therapy it claims could finally make headway.